Matrix Composites & Engineering (ASX:MCE) has rejected a confidential non-binding indicative proposal from Advanced Innergy Solutions regarding a potential reverse merger. The proposal involved Matrix ...

Chimeric Therapeutics (ASX:CHM) announced an update from its ADVENT-AML Phase 1B clinical trial, with two of the three evaluable patients achieving a complete response with incomplete blood count ...

Shares of Advanced Micro Devices (NASDAQ:AMD) surged by 5.7% in premarket trading to reach $119.02 after the company unveiled a new $6 billion share repurchase program. This move signals AMD's ...

Saudi Arabia’s sovereign wealth fund, the Public Investment Fund (PIF), is reportedly set to place an order for 30 Boeing (NYSE:BA) 737 MAX jets, according to Bloomberg News. The jets are intended for ...

Honda Motor (NYSE:HMC) on Tuesday announced a significant 24.5% decline in profit for the fiscal year ending in March, attributing the drop primarily to weakened vehicle sales in China. The Japanese ...

dorsaVi (ASX:DVL) is expanding its AI-powered video AI platform into the workplace safety market. The move follows strong demand from a major US franchise group and a leading Australian insurer, ...

Augustus Minerals (ASX:AUG) has executed a binding share purchase agreement to acquire 100% of ACM Contract Mining PNG, a Papua New Guinea-incorporated entity holding a third-in-line application for ...

Following the completion of the April trading period and a review of business segment forecasts, Engenco (ASX:EGN) has updated its outlook for FY25. While the company expects positive financial ...

Australia's federal government debt is on track to surpass $1 trillion as early as September, prompting economists to call for urgent fiscal reforms to preserve the nation's AAA credit rating. Current ...

Tesla's (NASDAQ:TSLA) new car sales in the United Kingdom took a sharp nosedive in April, plunging by 62% year-on-year to their lowest point in over two years, according to new data released on ...

Dexus (ASX:DXS) has reported its performance for the March quarter, underpinned by robust fundamentals in the Australian real assets market, including strong population growth, low unemployment, ...

Immutep (ASX:IMM) has announced results from Cohort B of its TACTI-003 Phase 2b trial, revealing a median overall survival of 17.6 months for patients with recurrent/metastatic head and neck squamous ...